CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

NCT06947460 PHASE1, PHASE2 RECRUITING

This is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), and primary Sjogren syndrome combined with pulmonary artery hypertension (pSS-PAH) receive CD19-BCMA CAR T cell therapy. The primary objective is to prospectively assess the safety of CD19-BCMA CAR T cell therapy in patients with SLE-LN, SSc, and pSS-PAH. The primary endpoint is the type and incidence of dose-limiting toxicity (DLT) within 28 days after CD19-BCMA CAR T cell infusion.

Details

Lead sponsor	Beijing GoBroad Hospital
Phase	PHASE1, PHASE2
Status	RECRUITING
Enrolment	45
Start date	Fri Apr 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jul 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Refractory Lupus Nephritis
• Systemic Sclerosis
• Primary Sjogren's Syndrome Combined With Pulmonary Hypertension

Interventions

• CD19-BCMA CAR-T cells infusion

Countries

China